Word: frayed
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...high caliber could not have kept everyone guessing up until the last moment. He must have assessed the very remote possibility of his success despite what his political soothsayers might have suggested. He knew well that the time was not yet ripe for him to jump into the fray. OM JULKA Moreland Hills, Ohio...
Lucien Bouchard, the charismatic leader of the separatist Parti Quebecois, has changed his mind about quitting the fray. Bouchard, who announced he was considering leaving politics after Quebec's referendum to secede from Canada was narrowly defeated last month, says he will seek to replace outgoing Quebec Premier Jacques Parizeau. "Bouchard has put regionalism ahead of a national role in government," says TIME's William McWhirter. "What he's done is say Quebec is more important than the country. And given his success in galvanizing Quebeckers during the referendum, he is the province's best chance at gaining independence. Bouchard...
...Silvermine Consulting Group, in Westport, Connecticut. "It's the most dramatic medical launch since Advil." Two acid blockers, Tagamet HB and Pepcid AC, have begun battling it out for market share, and two more--including the British colossus Zantac in over-the-counter form--will be joining the fray by next year...
...Pepcid's quick strike, Tagamet's ambitious counterattack and the row over advertising may look like mere skirmishes when Zantac 75 enters the fray. This acid blocker is the over-the-counter version of Zantac, the top-selling prescription drug in the world and the pride of Britain's Glaxo-Wellcome pharmaceutical stable. Prescribed for 240 million patients around the globe, Zantac last year generated $3.6 billion in sales, $2.1 billion in the U.S. And last month the over-the-counter Zantac 75 received a recommendation from an FDA advisory committee, virtually assuring its imminent approval for sale...
...firms in the fray or about to enter it are only too aware that their new heartburn drugs are bound to cannibalize their traditional antacid products. In touting Tagamet HB, for example, SmithKline has to avoid invidious comparisons with Tums, its antacid moneymaker, while J&J/Merck must tiptoe around any comparisons between Pepcid AC and its antacid, the much advertised Mylanta. Meanwhile, Switzerland's Ciba-Geigy has other worries. Though it has no acid blocker available that could bite into sales of Maalox, its bread-and-butter antacid, its competitors' new drugs almost certainly will...